SUBSCRIBE
SUBSCRIBE
News   Drug Development

Unique Structure Of Geron Corporation’s Telomerase Inhibitor Drug Promotes Anti-Tumor, Anti-Metastatic Activity In Lung Cancer Cells

February 15, 2007 | 
1 min read
MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced the publication of preclinical data that show specific structural elements of GRN163L contribute to its unique anti-tumor and anti-metastatic activity.
Preclinical
MORE ON THIS TOPIC
Business people and concepts vector art exit
Spinal muscular atrophy
Roche Ends Run for Muscular Atrophy Drug, Leaving Door Open for Competitors
March 20, 2026
 · 
2 min read
 · 
Tristan Manalac
Man walking on a long wavy path with flag at the end, persistence, determination and ultimate business success - 3D Render
FDA
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure
March 19, 2026
 · 
2 min read
 · 
Annalee Armstrong
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Diabetes
Lilly Builds Differentiated Profile for Triple-G Agonist With Late-Stage Diabetes Data
March 19, 2026
 · 
2 min read
 · 
Tristan Manalac
Insights
Inside the Race to Build the Next Generation of AI Drug Discovery Platforms
March 19, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker